Cabozantinib and Panitumumab for RAS Wild‐Type Metastatic Colorectal Cancer

LESSONS LEARNED: Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long‐term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Strickler, John H., Rushing, Christel N., Uronis, Hope E., Morse, Michael A., Niedzwiecki, Donna, Blobe, Gerard C., Moyer, Ashley N., Bolch, Emily, Webb, Renee, Haley, Sherri, Hatch, Ace J., Altomare, Ivy P., Sherrill, Gary B., Chang, David Z., Wells, James L., Hsu, S. David, Jia, Jingquan, Zafar, S. Yousuf, Nixon, Andrew B., Hurwitz, Herbert I.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2021
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176979/
https://ncbi.nlm.nih.gov/pubmed/33469991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13678
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars